Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The primary objective was to determine superiority of dulaglutide 1.5 mg versus placebo in HbA1c change at 26 weeks. RESEARCH DESIGN AND METHODS: This 52-week, multicenter, parallel-arm study (primary end point: 26 weeks) randomized patients (2:2:2:1) to dulaglutide 1.5 mg, dulaglutide 0.75 mg, exenatide 10 μg, or placebo (placebo-controlled period: 26 weeks). Patients were treated with metformin (1,500–3,000 mg) and pioglitazone (30–45 mg). Mean baseline HbA1c was 8.1% (65 mmol/mol). RESULTS: Least squares mean ± SE HbA1c change from baseline to the primary end point was −1.51 ± 0.06% (−16.5 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, −1.30 ± 0.06% (−14.2 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, −0.99 ± 0.06% (−10.8 ± 0.7 mmol/mol) for exenatide, and −0.46 ± 0.08% (−5.0 ± 0.9 mmol/mol) for placebo. Both dulaglutide doses were superior to placebo at 26 weeks (both adjusted one-sided P < 0.001) and exenatide at 26 and 52 weeks (both adjusted one-sided P < 0.001). Greater percentages of patients reached HbA1c targets with dulaglutide 1.5 mg and 0.75 mg than with placebo and exenatide (all P < 0.001). At 26 and 52 weeks, total hypoglycemia incidence was lower in patients receiving dulaglutide 1.5 mg than in those receiving exenatide; no dulaglutide-treated patients reported severe hypoglycemia. The most common gastrointestinal adverse events for dulaglutide were nausea, vomiting, and diarrhea. Events were mostly mild to moderate and transient. CONCLUSIONS: Both once-weekly dulaglutide doses demonstrated superior glycemic control versus placebo and exenatide with an acceptable tolerability and safety profile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another analog of human of GLP-1, but in once weekly administration, was similarly found to be superior to exenatide twice daily in reducing HbA1C, −1.51% vs. −0.99%.18”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [18]
In the citing paper
“The most common adverse events (AEs) reported with GLP-1RAs were gastrointestinal disorders, such as nausea, diarrhea, vomiting, and abdominal pain, etc (7–9).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [8]
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“American Indian 40 (14) 37 (13) 38 (14) 20 (14)”
ResultBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Cited by
Items 201–300 of 396
Dungan, K. M., Raz, I., Skrivanek, Z., Sealls, W., & Fahrbach, J. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12575 · Cited by 18
Mode of administration of dulaglutide: implications for treatment adherence
Amblee, A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s82866 · Cited by 17
Dilla, T., Alexiou, D., Chatzitheofilou, I., Ayyub, R., Lowin, J., & Norrbacka, K. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1275651 · Cited by 18
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
Galstyan, G. R., Анатольевна, К. Е., & Александровна, Ю. Е. (2017) · Diabetes Mellitus · doi:10.14341/dm8804 · Cited by 21
Napoli, R., Avogaro, A., Formoso, G., Piro, S., Purrello, F., Targher, G., & Consoli, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.039 · Cited by 18
Dalmazi, G. D., Coluzzi, S., BALDASSARRE, M. P. A., Ghit, A., Graziano, G., Rossi, M. C., Ciappini, B., Milo, M., Carrieri, F., Nicolucci, A., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.892702 · Cited by 22
Miao, X., Davoudi, M., Alitotonchi, Z., Ahmadi, E. S., Amraee, F., Alemi, A., & Afrisham, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01581-3 · Cited by 20
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
Li, Y., Gong, X., Găman, M., Hernández‐Wolters, B., Velu, P., & Li, Y. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14125 · Cited by 21
Makunts, T., Joulfayan, H., & Abagyan, R. A. (2024) · JMIRx Med · doi:10.2196/55976 · Cited by 14
Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus
Leiter, L. A., & Nauck, M. A. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-103969 · Cited by 16
Ishii, H., Madin-Warburton, M., Strizek, A., Thornton‐Jones, L., & Suzuki, S. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1431918 · Cited by 16
Yan, L., Li, L., Peng, Y. D., Song, G., Ye, S., Du, L. Y., Hou, J. N., & Ji, Q. H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0646-y · Cited by 17
Tan, X., Divino, V. M., Amamoo, J. J., Xie, L., Coyle, K. B., Gamble, C. L., Guevarra, M., Paprocki, Y., & King, A. A. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01354-2 · Cited by 16
Handelsman, Y., Wyne, K., Cannon, A., Shannon, M., & Schneider, D. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s14 · Cited by 14
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13224 · Cited by 14
Xia, Y., Gao, Z., Hao, Z., Ma, H., Duan, K., & Yang, C. (2023) · Medicine · doi:10.1097/md.0000000000035739 · Cited by 17
Basson, M., Ntais, D., Ayyub, R., Wright, D., Lowin, J., Chartier, F., Roze, S., & Norrbacka, K. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0321-0 · Cited by 15
Davidson, J. A., Manghi, F. P., Yu, M. B., Linetzky, B., & Landó, L. F. (2016) · Endocrine Practice · doi:10.4158/ep161337.or · Cited by 14
Chiang, C., Chang, Y., Yu, C.-C., See, X. Y., Wang, T. H., Xanthavanij, N., Song, J., Lo, S., Chiang, C.-H., Lake, L. L., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.020 · Cited by 15
Oita, M., Miyoshi, H., Ono, K., Nakamura, A., Cho, K. Y., Nomoto, H., Yamamoto, K., Omori, K., Manda, N., Kurihara, Y., et al. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej17-0303 · Cited by 13
Gentilella, R., Sesti, G., Vázquez, L. A., Sapin, H., Reed, V. A., Romera, I., & Pozzilli, P. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13853 · Cited by 16
Lee, J., Cho, Y. K., Kim, H. S., Jung, C. H., Park, J., & Lee, W. J. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s231272 · Cited by 14
Pan, H., Su, Y., Xie, Y., Wang, W., Qiu, W., Chen, W., Lu, W., Lu, Z., Wang, W., & Shang, A. (2020) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2020.1770268 · Cited by 13
GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice
Triplitt, C. L., & Solis‐Herrera, C. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607981 · Cited by 16
Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
HEILE, M. K., Wyne, K. L., Billings, L. K., Cannon, A. J., Handelsman, Y., & Shannon, M. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s42 · Cited by 16
Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors
Lear, S., Amso, Z., & Shen, W. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.02.008 · Cited by 16
Shi, L., Liu, X. M., Yong Quan, S. H. I., Li, Q. M., Ma, J. H., Li, Y. B., Du, L. Y., Wang, F., & Chen, L. L. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13075 · Cited by 13
Tirzepatide: Clinical review of the twincretin injectable
Krauss, Z., Hintz, A., & Fisk, R. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad080 · Cited by 12
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 17
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
GLP-1R in diabetes mellitus: from basic discovery to therapeutics development
Li, S., Huang, N., Wang, M., Huang, W., Luo, Y., & Huang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1610512 · Cited by 21
The role of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Onge, E. S., Miller, S. A., Clements, E. A., Celauro, L., & Barnes, K. (2017) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2017-0015 · Cited by 13
Advances in the treatment of type 2 diabetes: impact of dulaglutide
Thompson, A., & Trujillo, J. M. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s75452 · Cited by 13
Giorgino, F., Yu, M., Haupt, A., Milicevic, Z., & García-Pérez, L. (2019) · Diabetes, obesity and metabolism · doi:10.1111/dom.13844 · Cited by 11
Rose, T. N., Jacobs, M. L., Reid, D. J., Bouwmeester, C. J., Conley, M. P., Fatehi, B., Matta, T. M., & Barr, J. T. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.09.001 · Cited by 12
Urva, S., Levine, J. A., Schneck, K. B., & Tang, C. C. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2322072 · Cited by 12
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 15
Vahle, J. L., Byrd, R. A., Blackbourne, J. L., Martin, J. A., Sorden, S. D., Ryan, T. E., Pienkowski, T. P., Rosol, T. J., Snyder, P. W., & Klöppel, G. (2015) · Toxicologic Pathology · doi:10.1177/0192623315588999 · Cited by 11
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
Gentilella, R., Romera, I., Nicolay, C., Buzzetti, R., Vázquez, L. A., & Sesti, G. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0625-3 · Cited by 12
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Jiang, Y., Bai, H., Liu, G., Wang, S.-Y., Yin, L., Hou, Z.-T., Zhao, C., & Fan, G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1347684 · Cited by 12
Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide
Grunberger, G., Forst, T. M., Landó, L. F., Pechtner, V., Shaginian, R. M., Jia, N., & Gough, S. C. L. (2015) · Diabetic Medicine · doi:10.1111/dme.12833 · Cited by 11
Meece, J. D. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0491-1 · Cited by 16
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Which incretin-based therapy for type 2 diabetes?
Scheen, A. J. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61097-7 · Cited by 10
Kim, H. J., Park, S. O., Ko, S., Rhee, S. Y., Hur, K. Y., Kim, N. H., Moon, M. K., Lee, B., Kim, J. H., & Choi, K. M. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.6.423 · Cited by 12
Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes
Patel, D. K. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000112 · Cited by 10
Qie, S., Li, X., Wang, X., Liu, Y., Li, J., & Liu, G. (2020) · Endocrine · doi:10.1007/s12020-020-02193-9 · Cited by 12
Cheng, Z., Wang, S., Li, F., Jin, C., Mo, C., Zheng, J., Li, X., Liang, F., Yang, J.-K., & Gu, D. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70013 · Cited by 12
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Zhu, D., Wang, W., Tong, G., Ma, J., WEN, B., Zheng, X., Shi, B., Shuguang, P., Wang, K., Shi, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68165-7 · Cited by 9
Exacerbation of atrial fibrillation related to dulaglutide use
Lee, J., Umana, I. E., & Nguyen, J. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4223 · Cited by 9
The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes
Ruda, A. I., Ciobanu, D. M., Inceu, G., Rusu, A., & Román, G. (2022) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2425 · Cited by 9
GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
Gallwitz, B. (2015) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2015.11.01.21 · Cited by 9
Mody, R., Yu, M. B., Grabner, M., Boye, K. S., Teng, C., & Kwan, A. Y. M. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.09.011 · Cited by 10
Umpierrez, G. E., Pantalone, K. M., Atisso, C. M., Landó, L. F., & Patel, H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13662 · Cited by 9
Self-citationA systematic review of the safety of incretin-based therapies in type 2 diabetes
Evans, M., Bain, S. C., & Vora, J. P. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1057502 · Cited by 8
Guo, L., Zhang, B., Hou, J., & Zhou, Z. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00869-z · Cited by 8
Kwan, A. Y. M., Gerstein, H. C., Basile, J., Xavier, D., Maldonado, J. M., Raha, S., & Кониг, М. (2022) · Diabetes Care · doi:10.2337/dc21-1160 · Cited by 9
Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review
Teague, M., Martinez, A., Walker, E., El-Rifai, M., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.02.003 · Cited by 8
Jameshorani, M., Sayari, S., Kiahashemi, N., & Motamed, N. (2017) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2017.193 · Cited by 10
Bobu, A. M., Turliuc, Ș., Cucu, A. I., Onofriescu, A., Dascălu, C. G., Costea, C. F., Pătrășcanu, E., Morosan, A. P., Hăisan, A., Filip, C. N., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103536 · Cited by 7
Patel, H., Munir, K. M., Sutherland, S.-B., Karanikas, C. A., & Кониг, М. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00709-9 · Cited by 7
Sabina, M., & Alsamman, M. (2024) · Cardiology Research · doi:10.14740/cr1600 · Cited by 10
Petrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 9
Zangabad, P. S., Vasani, R. B., Tong, Z., Anderson, D., Rudd, D. A., Hick, C. A., Wootten, D. L., Sexton, P. M., Yan, L., Esser, L., et al. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400136 · Cited by 9
Kim, J.-Y., Yang, S., Lee, J. I., & Chang, M. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153502 · Cited by 7
Wasir, J. S., Mithal, A., Agarwal, P., & Mittal, A. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_424_18 · Cited by 8
Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes
Goldman, J. D. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015572653 · Cited by 7
Тихоненко, Е. В., Babenko, A. Y., & Shlyakhto, E. V. (2019) · Obesity and metabolism · doi:10.14341/omet9584 · Cited by 7
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Lv, L., Wang, Y., Xie, L., Noone, J. M., Alvarez, S., Zhang, Y., Song, Y., & Rotroff, D. M. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.018 · Cited by 6
Cui, H., Zhao, C., Lv, Y., Wei, M., Zhu, Y., Li, Y., Xia, Y.-H., Liu, Y., Tian, J., & Zhang, P. (2020) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00605-9 · Cited by 6
Htike, Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
MacIsaac, R. J. (2021) · Future Cardiology · doi:10.2217/fca-2020-0210 · Cited by 8
Ayesh, H., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2024) · Biomedicines · doi:10.3390/biomedicines12091943 · Cited by 5
Préparations insuliniques au cours de la dernière décennie.
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30034-8 · Cited by 5
Iwasaki, T., Kessoku, T., Higurashi, T., Taguri, M., & Yoneda, M. (2018) · Diabetology International · doi:10.1007/s13340-018-0348-0 · Cited by 6
Takehisa, Y., & Bando, H. (2020) · Edelweiss Journal of Biomedical Research and Review · doi:10.33805/2690-2613.113 · Cited by 5
Cui, H., Zhao, C.-Y., Lv, Y., Wei, M., Zhu, Y., Ma, X., Xia, Y.-H., Tian, J., Ma, Y., Liu, Y., et al. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00665-x · Cited by 5
Guo, L., Li, L., Yu, Q., Wang, N., Chen, J., Wang, Z., & Ding, Y. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01268-2 · Cited by 5
Dunn, T. J., Zhu, Y., Gronroos, N. N., Xie, L., Sargent, A., Gamble, C. L., & Billings, L. K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112162 · Cited by 5
Agonistas de GLP-1 en el control glucémico y ponderal de la diabetes tipo 2. Nuevas perspectivas
Alonso, S. P., Valdés, S., & Doulatram‐Gamgaram, V. K. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107042 · Cited by 4
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Lauri, G., Arcidiacono, P. G., Facciorusso, A., Capurso, G., & Tacelli, M. (2026) · Pancreatology · doi:10.1016/j.pan.2026.04.005 · Cited by 4
Oh, S., Chon, S., Ahn, K. J., Jeong, I., Kim, B.-J., & Kang, J. G. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.3.177 · Cited by 4
Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
Chilton, R. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000483 · Cited by 4
Jódar, E., Romera, I., Wang, Q., Roche, S. L., & García‐Pérez, L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14615 · Cited by 5
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
Emoto, M., Oura, T., Matsui, A., Kazama, H., & Iwamoto, N. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0365 · Cited by 4
Li, Y. M., Zhang, L. H., Li, X. J., Zhang, B., Hou, J. N., & Tong, N. W. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00799-w · Cited by 5
Igg4-Related Disorder and Endocrine Diseases: A Review of the Literature
Bashier, A. M., & Harifi, G. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000631 · Cited by 4
Grandy, S., & Shaunik, A. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000643 · Cited by 6
Singh, A. K., & Singh, R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1318061 · Cited by 4
Inceu, G. V., Crăciun, A.-E., Ciobanu, D. M., Berchisan, A., Fodor, A., Bala, C., Roman, G., & Rusu, A. (2025) · Medicina · doi:10.3390/medicina61081343 · Cited by 3
“While the efficacy of GLP-1 RAs in lowering hemoglobin A1c (HbA1c) and promoting weight loss has been well documented in clinical trials [9,10], there is a large variability in response.”
Metadata
- Authors
- Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M.
- Affiliations
- Redwood Clinic, Spokane, WA
- Texas Diabetes & Endocrinology (US)
- University of Hawaiʻi at Mānoa (US)
- American Telemedicine Center of Puerto Rico, San Juan, PR
- University Hospital Autonomous University of Nuevo León, Monterrey, Mexico
- Eli Lilly (United States) (US)
- Corresponding author
- Lakshmanan, Mark
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-07-12
- Volume
- 37
- Issue
- 8
- Pages
- 2159-2167
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2104252114
- Cited by
- 396
- References
- 24
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 26 · 2023: 27 · 2022: 15 · 2021: 25 · 2020: 31 · 2019: 31 · 2018: 34 · 2017: 38 · 2016: 47 · 2015: 44 · 2014: 10
- FWCI
- 37.26
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-10-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- dulaglutide, exenatide, type 2 diabetes, GLP-1 receptor agonists, pioglitazone, metformin, HbA1c, glycemic control, hypoglycemia, drug safety, combination therapy, dose comparison, HbA1c targets, weight gain, adverse events
- MeSH terms
- Pioglitazone, Exenatide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Middle Aged, Peptides, Recombinant Fusion Proteins, Venoms, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.